Industry
Featured experience
Amgen $28.5 billion Horizon Therapeutics acquisition financing
We advised the lender parties on the financing
Forbion European Acquisition $138 million combination with enGene
We advised Forbion European Acquisition on its de-SPAC transaction
Bausch + Lomb $630 million IPO
We are advising Bausch Health on the separation of its eye health business into a new public company, Bausch + Lomb
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Labcorp $2 billion senior notes offering
The investment-grade notes are due 2030, 2032 and 2034
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
MBX Biosciences $188 million IPO
The shares are listed on the Nasdaq Global Select Market
Terns Pharmaceuticals $173 million stock and pre-funded warrants offering
The shares are listed on the Nasdaq Global Select Market
Ionis Pharmaceuticals $500.3 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Illumina $500 million notes offering
The 4.65% investment-grade notes are due 2026
Jazz Pharmaceuticals $1 billion exchangeable senior notes offering
The exchangeable notes are due 2030
McKesson $2.49 billion acquisition of controlling interest in Core Ventures
We are advising McKesson on the transaction
Owens & Minor $1.4 billion Rotech acquisition financing
We are advising the lead arrangers on the financing
Eli Lilly $5 billion notes offering
The investment-grade notes are due 2027, 2029, 2034, 2054 and 2064